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Abstract: Taking advantage of the radiation properties of 99mTc and 186/188Re and the photophysical
characteristics of the {M(CO)3}+ moiety (M = Re), we developed a multifunctional silica platform
with the theranostic pair 99mTc/Re with high potential for (nano)medical applications. Starting with a
general screening to evaluate the most suitable mesoporous silica construct and the development
of appropriate chelate systems, multifunctional mesoporous silica microparticles (SBA-15) were
synthesized. These particles act as a model towards the synthesis of the corresponding nanoconstructs.
The particles can be modified at the external surface with a targeting function and labeled with the
{M(CO)3}+ moiety (M = 99mTc, Re) at the pore surface. Thus, a silica platform is realized, whose
bioprofile is not altered by the loaded modalities. The described synthetic procedures can be applied
to establish a target-specific theranostic nanoplatform, which enables the combination of fluorescence
and radio imaging, with the possibility of radio- and chemotherapy.
Keywords: technetium; rhenium; complexes; mesoporous silica; MCM-41; SBA-15; theranostic;
multimodality; radioprobe
1. Introduction
For many decades, the nuclear isomer technetium-99m (99mTc, t1/2 = 6 h, Eγ = 141 keV) has been the
most frequently used radio metal for applications in nuclear medical diagnostics [1–5]. In combination
with isotopes 186 and 188 of its heavier homolog rhenium (186/188Re), it represents one of the first
“theranostic pairs” for nuclear medical diagnosis and therapy [6]. Recently, a conceptual extension
of the “theranostic pair” Tc/Re was described by the combination of a 99mTc-based bio-mimetic with
its organometallic but non-radioactive rhenium homologue [7]. The rhenium complex should be
therapeutically active through its structure, while the 99mTc homologue allows for visualizing the
pharmacology. Besides the use of Tc and Re as a “theranostic pair”, Stephenson et al. demonstrated
that the two homologues allow the development of multimodal imaging probes [8]. A fluorescent
Re-complex and the analogous 99mTc-complex provide the direct combination of optical imaging with
high spatial resolution (in vitro) and radioimaging with sensitive detection of biological processes deep
in the body (in vivo). By combining the multimodality of the {M(CO)3}+ moiety (M = 99mTc, Re) with
the theranostic properties of the 99mTc/186/188Re pair, a multifunctional system is realized, which can be
applied for diagnosis (radio and UV imaging) and (radio) therapy. This represents a new strategy for the
application of Tc and Re in medicine and will enable new opportunities for these two elements. To apply
multimodality probes in medicine, they have to be target-specific. To design a target-specific molecular
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scaffold that combines all of the described Tc/Re-based modalities is challenging. Attractive alternatives
are target-specific mesoporous nanoplatforms, which can incorporate the different modalities. An
advantage of this approach is that the bioprofile of the target-specific mesoporous nanoplatform is not
altered by the incorporated modality (Figure 1).
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Currently, multifunctional nanoplatforms are a focus in nanomedicine [9]. Nanoparticles are
ideal for combining different modalities and exhibit several advantages as compared to traditional
diagnostic and therapeutic methods. They can easily integrate more than one kind of imaging or
therapeutic agent. Large amounts of imaging agents or drugs can be introduced through chemical
conjugation or simple loading due to the large surface area or interior cargo volume of the nanoparticles.
Moreover, nanoparticles can target disease sites for drug delivery and imaging through physicochemical
optimization of size and surface properties, and especially through the attachment of specific targeting
moieties. Alteration of physicochemical properties can also be used to optimize the circulation time
in the blood [10]. A further interesting feature of nanoparticles in radiopharmacy is the possibility
to accumulate more than one radioactive moiety per target receptor. This leads to higher activity
at the target site (amplification effect) as compared to directly labeled targeting molecules, which
can only deliver one radioactive moiety per target receptor [11]. These beneficial properties of
nanoparticles lead to a better contrast of the diagnostic image. The overall radioactivity can be
reduced, leading to lower dose rates for the patients. In the past, different nanomaterials have been
labeled with 99mTc in a nonspecific fashion, such as magnetic nanoparticles [12–15], organo-germanium
compounds [16], carbon nanotubes [17], fullerene derivatives [18], polymers [19], pullulan acetates [20],
chitosans [21,22], and tripalmitins [23]. In all these approaches, [99mTcO4]− activity has been reduced
in the presence of the nanoparticles. This leads to a random distribution of 99mTc at the surface of
the nanoparticles and an undefined binding mode at the particle surface. This unspecific labeling
method is fast, but unambiguous characterization of the labeled nanoparticles is challenging. For
the preparation of well-defined mesoporous nanoparticles, whose external and pore surface can be
addressed independently at different stages of the synthesis, a specific and reproducible method to
bind technetium and rhenium is required. Furthermore, developing a well-defined labeling procedure
for nanoparticles with 99mTc can serve as a useful tool to investigate general aspects of nanoparticles,
such as entry routes, pharmacokinetics, and the molecular mechanism of nanoparticle toxicity [24].
Mesoporous silica particles show highly interesting properties that make them promising candidates
for target-specific, multifunctional nanoplatforms (Figure 1). Especially, selective functionalization of
the external and the pore surface area as well as cargo loading are established features for this type of
material [25–29]. Besides applications in catalysis [30–35] and sensing [36], MCM-41 (Mobil Composition
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of Matter No. 41), a prominent representative of mesoporous silica particles, was first proposed as
a drug delivery system in 2001 [37]. Since then, extensive research efforts have been dedicated to
this subject, leading to sophisticated systems for drug delivery and controlled drug release [38–43].
Therefore, mesoporous silica particles enable the development of carrier systems, which combine
targeting moieties, Tc- and Re-based imaging functions (radio- or UV-labels), and drug loading in a
well-defined way. This creates multifunctional nanoplatforms, which are extremely suited for future
applications in the evolving field of nanomedicine and personalized medicine [44].
Herein, we describe the development of a Tc and Re based multifunctional silica microplatform.
This platform acts as a model towards the synthesis of the corresponding nanoconstructs. Starting
with a general screening of different mesoporous silica microparticles to evaluate the most suitable
construct and the development of appropriate chelate systems, multifunctional mesoporous silica
particles, such as SBA-15 (Santa Barbara Amorphous type material No. 15) and spherical SBA-15
(sSBA-15), are synthesized. These particles can be labeled with the {M(CO)3}+ moiety (M = 99mTc, Re)
at the pore surface.
2. Results and Discussion
2.1. Evaluation of Mesoporous Silica Particles
The term mesoporous silica represents a large family of compounds with a plethora of properties.
To understand which type of mesoporous silica particle is suitable as a theranostic platform, in a
first step a variety of different types of mesoporous silica microparticles, such as MCM-41 (Mobil
Composition of Matter No. 41) [45], ASNCs (arrays of silica nanochannels) [46], and SBA-15 (Santa
Barbara Amorphous type material No. 15) [47] were evaluated (for details see Supplementary
Materials). All studied materials are established mesoporous silica microparticles. The screening was
done by comparing the labeling performance of the functionalized silica microparticles, applying a
new 99mTc labeling strategy [48,49]. The (3 + 2)-cycloaddition reaction of the [99mTcO3(tacn)]+ complex
(tacn = 1,3,5-triazacacyclononane) with surface-grafted norbornene proceeds stereoselectively and
with high reaction rates [50]. Therefore, it is an excellent method for fast and efficient screening of
different materials. For this screening, 5-(bicycloheptenyl)triethoxysilane (NorboSi) was grafted to the
surfaces of the silica particles under study in the first step. In the second step, [99mTcO3(tacn)]+ was
reacted with these modified particles. Progress of labeling can be monitored by the decrease of the
activity in the solution over time. Furthermore, the labeled particles were decomposed in 1M NaOH as
control and the released activity was correlated to the observed decrease of activity in the solution
by radio-HPLC. Figure 2 shows the labeling progress for two representative examples of the studied
microparticles (MCM-41 and SBA-15).
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groups (blue). Percentages in brackets represent the carbon content of these particles, determined by
elemental analysis (EA C). Conditions: 10 mg NorboSi modified silica particles suspended in 2 mL
saline solution, addition of 2 mL [99mTcO3(tacn)]+ solution, sonication for 2 h, start temperature 25 ◦C
(increased to 40 ◦C over the reaction time of 2 h).
The screening disclosed a remarkable difference in the labeling performance of the modified
silica particles depending on the porosity. Whereas SBA-15 particles showed very fast and almost
complete labeling (more than 90% labeling yield in less than 1 min reaction time), the MCM-41 particles
had a much slower labeling rate. After 2 h reaction time, a labeling yield of only 60% was observed.
Analysis of the gained data of all studied materials shows that silica particles with more accessible
surface area lead to higher rates for the 99mTc-labeling. For mesoporous silica microparticles, most
of the surface area (roughly 90%) is located in the pores. A larger pore diameter gives enhanced
access for [99mTcO3(tacn)]+ to the norbornene decorated pores. As a consequence, particles with larger
average pore size, such as SBA-15 (7–7.5 nm), show superior labeling performance as compared to
particles with significantly smaller average pore size, such as MCM-41 (4 nm). The amount of grafted
norbornenesilane (as determined by elemental analysis) has no significant influence as compared to the
much more crucial pore size and accessible surface area. Due to the outstanding labeling performance
of SBA-15 microparticles in contrast to all other tested silica particles, only this class of particles was
considered for further investigation. In contrast to the synthetic procedure for SBA-15 microparticles,
no synthetic procedures for well-defined SBA-15 nanoparticles are established. However, we expect
that the herein reported procedures for the synthesis of bifunctionalized SBA-15 microparticles can be
applied without further modifications for the synthesis of a SBA-15-based theranostic nanoplatform.
2.2. Synthesis of Chelators for Surface Modifications
By applying the (3 + 2)-cycloaddition [99mTcO3(tacn)]+ with alkenes, an efficient new method
was established to study the accessibility of functional groups (NorboSi) at silica particle surfaces.
However, the high-valent chemistry of the {99mTcO3}+ was not established for theranostic applications
due to the different redox potentials of the elements Tc and Re at their highest oxidation states [48].
This would limit a potential target-specific NorboSi@SBA-15 construct to radioimaging with 99mTc
and conventional drug loading, disregarding the full potential of the theranostic pair 99mTc/Re.
Therefore, an alternative approach with the {M(CO)3}+ core (M = Re, 99mTc) and SBA-15 particles was
selected. For the development of theranostic nanoplatforms for (nuclear) medical applications, the
bisquinoline/{M(CO)3}+ (M = Re, 99mTc) system is very well suited. The correlation of radioimaging and
fluorescence studies with this system in single amino acid chelates was reported by Stephenson et al. [8].
SBA-15 particles carrying tridentate bisquinoline ligands enable the coordination of {99mTc(CO)3}+ for
radioimaging, {185/187Re(CO)3}+ for optical imaging, and {186/188Re(CO)3}+ for radiotherapy. Aiming
at the synthesis of SBA-15 particles carrying bisquinoline chelates, a successive synthesis of the
bisquinoline moiety (first by grafting of aminoalkyltriethoxysilane, followed by reductive amination
with 2-quinolinecarboxaldehyde) at the SBA-15 surface is attractive. However, previous studies
have shown that for this particular chelate, such a synthetic procedure does not lead to well-defined
particles but generates a mixture of bi- and tridentate chelates at the silica surface [51]. Therefore,
functionalization of SBA-15 by grafting of bisquinoline trialkoxysilanes is preferred. Different
bisquinoline moieties with appropriate terminal substituents for the attachment of trialkoxysilanes
have been synthesized (Scheme 1) in direct reductive amination.
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Scheme 1. Synthesis of different bisquinoline moieties with appropriate terminal substituents for the
attachment of trialkoxysilanes. Reaction time was 2–25 h at room temperature. Note: STAB = sodium
triacetoxyborohydride; DCE = 1,2-dichloroethane.
All compounds were isolated and characterized (see Supplementary Materials). The carboxyl
group was introduced into the bisquinoline moiety by a one-step reaction with 4-aminobutyric acid
(1d) or in a two-step procedure via deprotection of 1b (Scheme 2).
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evaporation of a l solution of [1c-4 ]( F ) (Figure 3). The chloride anion obviously originated
fro the solvent. In the structure of [1c-3 ] l( F )·( F ), t o trifluoroacetic aci ( F ) anions
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aliphatic tertiary amine is not (for crystallographic details see Supplementary Materials). This finding
is in contrast with the expected pKa values of TFA and amines in solution. This rare structural motif of
doubly-protonated pyridine rings pointing to a common hydrogen acceptor despite the presence of
the more basic aliphatic nitrogen of the bispicolylamine has been described before [52,53].
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bond formation of 3-aminopropyltriethoxysilane (APTES) with the acid bisquinolin moiety 1d is the
most efficient synthetic approach (Scheme 3).
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with dichloromethane (DCM) is sufficient to obtain the product in high purity. Tetramethylurea,
the only side product, does not interfere with the subsequent grafting onto silica particles. As an
alternative, the direct reductive amination of 2-quinolinecarboxaldehyde with APTES is a direct and
efficient synthetic pathway (Scheme 4).
The ethoxysilane groups tend to hydrolyze and subsequently cross-link. This undesired side
reaction has been addressed with EtOH for quenching of the residual reducing agent and C-18 flash
chromatography purification. The isolated bisquinolinepropyltriethoxysilane (3) is stable as a solid
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under ambient conditions over a period of several months. To evaluate the optimal reaction condition
for the bifunctionalization of SBA-15 particles, compound 3 was grafted in high (160 M) and low (4 M)
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Subsequent grafting of 3 to SBA-15 particles (2 h sonication, 60 ◦C).
The intact porous network of the modified SBA-15 particles (3@SBA-15) and successful grafting
to the external surface as well as to the pore surface was confirmed by determining the decrease of the
pore volume, the average pore diameter, and the total specific surface area (Table 1).
Table 1. N2-sorption values for SBA-15 and 3@SBA-15 particles, which contain 0.37 mmol 3/g particles
(determined by elemental analysis).
Particles Average Pore Size [nm] Total Pore Volume [cm3/g] BET Surface Area [m2/g]
SBA-15 7.0 0.75 570
3@SBA-15 6.8 0.64 441
The integrity of the grafted 3 was shown by decomposing the particles in 1M NaOD in D2O
and subsequent analysis of the solution by 1H-NMR and HR-ESI MS (high resolution-electrospray
ionization mass spectrometry); an analytical strategy that was recently developed by Farinha and
coworkers [56]. HR-ESI and 1H-NMR allowed for unambiguous characterization of the hydrolyzed
form of 3 and showed the release of EtOD due to the hydrolysis of Si–OEt groups not involved in
the binding to SBA-15. Quantification of the 3@SBA-15 particles with high 3 content by elemental
analysis showed 0.37 mmol of 3 per g of SBA-15, which correlates to 0.33 molecules of 3 per nm2 surface
of SBA-15. For comparison, applying 3 in lower concentrations for the synthesis led to 3@SBA-15
particles containing 0.08 mmol 3 per g particles.
Since 3 is highly stable, an alternative method for the synthesis of 3@SBA-15 is the co-condensation
approach. This led to microparticles showing high loading and homogeneous distribution of the
functionality over the complete porous network. Detailed synthetic procedures for all syntheses are
described in the supplementary.
2.3. Reactions of Bisquinoline Molecules with the {M(CO)3}+ Moiety (M = Re, 99mTc)
The chelates 1a, 1b, 1e, and 3 were reacted with (NEt4)2[ReBr3(CO)3] and the products
[(1a)Re(CO)3]+, [(1b)Re(CO)3]+, [(1e)Re(CO)3]+, and [(3)Re(CO)3]+ (3-Re) were isolated and
fully characterized. Single crystals, suitable for X-ray diffraction analysis, were obtained for
[(1a)Re(CO)3](PF6), [(1b)Re(CO)3](PF6) and [(1e)Re(CO)3](PF6) by vapor diffusion (Figure 4).
Furthermore, the photophysical properties of 3-Re were studied. The UV–Vis spectrum of 3-Re
shows a maximum absorbance at 323 nm with an extinction coefficient of 13696 M−1·cm−1 in CHCl3
under ambient conditions. The emission spectrum shows two distinct emissions at 426 and 546 nm.
These data are in good agreement with Stephenson et al [8]. Under an inert gas atmosphere (N2), two
emission maxima at 383 and 566 nm can be observed. The lifetime of the excited state determined in
Inorganics 2019, 7, 134 8 of 20
CHCl3/N2 is 12.5 µs. This is long enough to enable time-gating techniques, which are necessary to
overcome interferences from endogenous fluorescence during in vitro imaging studies [8].
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Grafting of 3-Re onto SBA-15 particles or solid phase supported reaction of 3@SBA-15 with
[Re(H2O)3(CO)3]+ results in 3-Re@SBA-15 particles (Scheme 5). HPLC of the reaction solution of
the reaction of 3-Re with SBA-15 particles (route a)) did not show any release of [Re(H2O)3(CO)3]+.
Therefore, it can be assumed that this reaction yields 3-Re@SBA-15 particles, which do not contain
uncoordinated 3. This was confir ed by the addition of [99mTc(H2O)3(CO)3]+ to these particles,
which did not lead to a labeling of the particles. However, in the context of potential nuclearmedical
applications, synthetic route a) would require a two-step procedure, starting with the synthesis of
3-186/188Re, followed by the grafting process. The increased complexity of this synthetic procedure
reduces its potential for clinic applications. From a theranostic point of view, the second approach
(synthetic route b)) has higher relevance due to a one-step labeling procedure. Aiming to establish a
feasible labeling for medical applications with the radio isotopes 186/188Re and 99mTc, [Re(H2O)3(CO)3]+
was chosen as a precursor for these reactions. In contrast to [Re(Br)3(CO)3]+, this precursor allows
for a direct translation of the model reaction with [Re(H2O)3(CO)3]+ into a labeling procedure with
[186/188Re(H2O)3(CO)3]+ and [99mTc(H2O)3(CO)3]+. Labeling of 3@SBA-15 particles, which contained
0.08 mmol 3/g particles (determined by EA) with an excess of [Re(H2O)3(CO)3]+, yielded 3-Re@SBA-15
particles with an Re loading of 0.077 mmol/g particles (determined by ICP-MS). The incomplete
occupation of the bisquinoline ligands at the surface of these fluorescent 3-Re@SBA-15 particles
allows for subsequent labeling with [99mTc(H2O)3(CO)3]+ in a second step (detail see Supplementary
Figure S4.4.3). For both synthetic routes, the CO bands in the IR spectrum clearly indicate successful
coordination of the {Re(CO)3}+ core (Figure 5). The CO vibrations of 3-Re@SBA-15 (2026, 1901, and 1981
cm−1) are in good agreement with the vibrations found for the 3-Re (2025 and 1901 cm−1, Supplementary
Figure S4.2.4.1). For comparison, the CO vibrations of the precursor complexes [ReBr3(CO)3]2− and
[Re(H2O)3(CO)3]+ can be observed at 1997 and 1844, and 2037 and 1916 cm−1, respectively [57].
The intensive bands at 1043 cm–1 can be assigned to Si–O vibrations of the bulk material.
The labeling of 3@SBA-15 with [99mTc(H2O)3(CO)3]+ (Scheme 5, synthetic route b)) to yield
3-99mTc@SBA-15 was fast, with a labeling yield > 99%. Detailed information for this labeling procedure
can be found in the Supplementary Materials (Supplementary Figure S4.3.4). As for the screening of
different silica materials, the labeling progress was indirectly analyzed by determining the decrease
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of activity in the solution. Prior to the reaction, radio-HPLC of the solution shows a clear signal
for the [99mTc(H2O)3(CO)3]+ complex at 5.5 min (Figure 6). After 15 min at 100 ◦C (microwave),
coordination of the {99mTc(CO)3}+ onto the silica particles was confirmed by radio-HPLC. In addition,
gamma counting of the filtered reaction solution showed a decrease of activity in the solution to almost
background level. Since 3 is randomly distributed over the surface of these model particles, the labeling
with 99mTc is not preferential in the pores.
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2.4. Synthesis and Labeling of a Bifunctional SBA-15 Construct with Re and 99mTc  
For the synthesis of a novel (nano)platform for theranostic applications, a bifunctionalized SBA-
15 microparticle model construct was realized. In the synthesized model, a fluorescent dye, grafted 
preferentially to the external surface of the SBA-15 particles, mimics the targeting function. This was 
Figure 5. Comparison of the IR spectra of SBA-15 particles (black) and 3-Re@SBA-15 particles (red),
synthesized by the reaction of [Re(H2O)3(CO)3]+ with 3-@SBA-15 (synthetic route b in Scheme 5). The
CO vibrations at 2026, 1901, and 1891 cm−1 show the coordination of the {Re(CO)3}+ moiety to 3.
2.4. Synthesis and Labeling of a Bifunctional SBA-15 Construct with Re and 99mTc
For the synthesis of a novel (nano)platform for theranostic applications, a bifunctionalized SBA-15
microparticle model construct was realized. In the synthesized model, a fluorescent dye, grafted
preferentially to the external surface of the SBA-15 particles, mimics the targeting function. This
was achieved with short reaction time, an apolar solvent (hexane), and a directing silane, such as
3-aminopropyltrimethoxyethoxyethoxysilane (APTMEES) [26]. Accordingly, the average pore size of
the SBA-15 particles re ained invariant upon the grafting of APTMEES (see Supplementary Materials)
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in contrast to the grafting of 3 to unmodified SBA-15 particles. Subsequently, the grafted amino
groups of APTMEES were reacted with the red emitting dye eosin isothiocyanate (EOITC). In the third
step, 3 was grafted to the SBA-15 particles at the still accessible surface. Finally, the bifunctionalized
EOITC/3@SBA-15 particles were labeled with the {M(CO)3}+ (M = Re, 99mTc) precursors (Scheme 6).
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2.4. Synthesis and Labeling of a Bifunctional SBA-15 Construct with Re and 99mTc  
For the synthesis of a novel (nano)platform for theranostic applications, a bifunctionalized SBA-
15 microparticle model construct was realized. In the synthesized model, a fluorescent dye, grafted 
preferentially to the external surface of the SBA-15 particles, mimics the targeting function. This was 
Figure 6. Idealized picture of the labeling of 3@SBA-15 with [99mTc(H2O)3(CO)3]+. Since 3 is randomly
distributed over the surface of these model particles, the labeling with 99mTc is not preferential in
the pores. The radio-HPLC traces show the activity in the reaction solution. Left: The γ-signal of
[99mTc(H2O)3(CO)3]+ is observed at 5.5 min (reaction time = 0). Right: almost quantitative coordination
of [99mTc(H2O)3(CO)3]+ at the 3@SBA-15 particles (reaction time = 15 min) evidenced by disappearance
of the 5.5 min peak.
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Scheme 6. Synthesis of bifunctionalized SBA-15 particles (SiP = SBA-15, spherical SBA-15 (sSBA-15)).
Step 1: Grafting of APTMEES (10 min, room temperature). Step 2: Coupling of the fluorescent dye
eosin isothiocyanate (EOITC) to the surface-grafted a ino groups (16 h, roo te perature). Step 3:
Grafting of 3 (2 h, 40 ◦C). Step 4: Labeling of the EOITC/3@SBA-15 particles with {M(CO)3}+ ( = Re,
99mTc) precursors (pH 7; Re: 45 in, 100 ◦C; 99mTc: 15 min, 100 ◦C).
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Confocal laser scanning microscopy (CLSM) images of spherical SBA-15 (sSBA-15) prepared
according to Scheme 6 show the location of the fluorescent moiety within the particles (Figure 7).
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Figure 7. Selective bifunctionalization of sSBA-15 particles visualized by confocal laser scanning
microscopy (CLSM): (a) red emission of the EOITC dye; (b) green emission of the 3-Re complex.
By choosing different excitation wavelengths, the two moieties EOITC and 3-Re can be excited
separately in the same particle. Optical slices in the center of the particles were selected and
representative images are shown in Figure 7. The red emission assessed the preferential attachment of
EOITC on the external surface. The “loading” of the {Re(CO)3}+ complex to the pore surface is depicted
by the green emission of the 3-Re complex. Finally, the bifunctional EOITC/3@sSBA-15 particles
were labeled with [99mTc(H2O)3(CO)3]+ (Scheme 6, step 4). The reaction of [99mTc(H2O)3(CO)3]+
with EOITC/3@sSBA-15 (5–15 MBq, pH 7, 15 min, 100 ◦C, microwave) led to labeling yields of 79%.
Benchmarking this result, monofunctionalized particles that contained only 3 (3@sSBA-15) were
reacted with [99mTc(H2O)3(CO)3]+ under the same labeling conditions, with a yield of 80%. The
lower labeling yield of the 3@sSBA-15 particles (80%) vs. the 3@SBA-15 particles (>99%) described
earlier in this report can be rationalized by the broader pore size distribution of the sSBA-15 particles.
However, sSBA-15 particles had to be utilized to visualize the selective functionalization of the silica
particles by CLSM. Further labeling studies of [99mTc(H2O)3(CO)3]+ with the precursor particles
APTMEES/3@sSBA (Scheme 6, step 1), showed a labeling yield of only 68%. The decrease of 11%
labeling yield (APTMEES/3@sSBA vs. EOITC/3@sSBA-15) has to be ascribed to electrostatic repulsion
of the positively charged [99mTc(H2O)3(CO)3]+ molecules and the protonated amines of the APTMEES
(saline solution, pH 7).
We show in this feasibility study synthetic pathways and procedures towards a SBA-15-based
target-specific theranostic nanoplatform, utilizing the theranostic pair 99mTc/Re. This platform enables
the combination of optical (fluorescence) and radio imaging with radio- and chemotherapy. The
translation into a theranostic nanoplatform can be realized as soon as procedures for the synthesis of
well-defined, non-agglomerated SBA-15 nanoparticles have been established.
3. Materials and Methods
Caution: 99mTc is a γ-emitter. All experiments have to be performed in laboratories approved for
working with low-level radioactive materials.
All chemicals were of reagent-grade quality or higher and were obtained from commercial
suppliers. Solvents were used as received or dried over molecular sieves. Na[99mTcO4] in 0.9% saline
was eluted from a 99Mo/99mTc Ultra-Technekow FM generator purchased from Mallinckrodt Medical
B.V. (Petten, The Netherlands). [99mTc(H2O)3(CO)3]+ was synthesized according to an adapted version
of a published procedure [58]. The [99mTcO4]– eluate (1–2 mL, obtained from the 99Mo/99mTc generator)
was added to a N2-flushed microwave vial containing Na2(BH3CO2) (4 mg, 0.040 mmol), disodium
tartrate dihydrate (7.0 mg, 0.030 mmol), and disodium tetraborate pentahydrate (7 mg, 0.024 mmol),
and heated in a microwave reactor for 10 min at 110 ◦C. Finally, the pH of the solution was adjusted
to pH 7 by the addition of 80–100 µL 1 M HCl. The [99mTcO3(tacn)]+ was synthesized according a
literature procedure [59].
Silica particles used in this study were of the MCM-41 and SBA-15 types. Due to their irregular
morphological properties, such as size and shape, they are not suited for optical analysis by CLSM.
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For that purpose, large spherical particles of the SBA-15 type (sSBA-15) were chosen. Besides
these well-known microparticles of MCM-41 and SBA-15, hexagonal arrays of silica nanochannels
(ASNCs), MCM-41-nanoparticles, and MCM-41 particles with various pore sizes were used in the initial
screening. The particles were synthesized following literature procedures (sSBA-15 [26], ASNCSs [60],
all others [61]). Characteristics of the applied silica particles are summarized in table S1 in the
supplementary information.
High-resolution mass spectrometry (HR-ESI-MS) was performed on a Bruker maXis QTof
high-resolution mass spectrometer (Bruker GmbH, Bremen, Germany).
1H and 13C-NMR spectra were recorded in deuterated solvents on a Bruker AV-400 or Bruker
AV-500 MHz spectrometer at 300 K. 13C-NMR spectra were proton decoupled. The chemical shifts (δ)
are reported in ppm relative to residual solvent peaks (dmf-d7 1H: 8.03 ppm, 13C: 163.15 ppm; CDCl3:
1H: 7.26 ppm, 13C: 77.16 ppm; MeOD: 1H: 3.31 ppm, 13C: 49.00 ppm; Acetone-d6: 1H: 2.05 ppm, 13C:
29.84 ppm). The abbreviations for the peak multiplicities are as follows: s (singlet), d (doublet), dd
(doublet of doublets), t (triplet), q (quartet), m (multiplet), br (broad). 29Si-NMR spectra were recorded
on a Bruker AV-500 MHz.
Gamma-counting of the 99mTc solutions was performed on a COBRA 5002 (Packard Instrument,
Meriden, USA). Half-life time corrections for the labeling of silica particles were neglected due to the
sequential measurement of the samples, with less than 5 min between two samples. Labeling of silica
particles: The initial activity of the 99mTc-solutions was determined prior to the addition of the particle
suspension. According to the dilution (factor 2), the activity for t = 0 min was calculated.
HPLC analyses were performed on a Merck Hitachi LaChrom L 7100 pump coupled to a Merck
Hitachi LaChrom L7200 tunable UV detector (Hitachi, Tokyo, Japan) and a radiodetector. UV–Vis
detection was performed at 250 nm. The detection of radioactive 99mTc complexes was performed
with a Berthold LB508 (Berthold Technologies, Bad Wildbad, Germany) radiodetector equipped
with a bismuth germanium oxid (BGO) cell. Separations were achieved on a Macherey–Nagel C18
reversed-phase column (nucleosil 10 ml, 250/3 mm) using a gradient methanol (solvent A) and 0.1%
trifluoroacetic acid (solvent B). Applied HPLC gradient: 0–3 min: 0% A, 100% B; 3–3.1 min: 0–25%
A, 100–75% B; 3.1–9 min: 25% A, 75% B; 9–9.1 min: 25–34% A, 75–66% B; 9.1–18 min: 34–100% A,
66–0% B; 18–25 min: 100% A, 0% B; 25–25.1 min: 100–0% A, 0–100% B; 25.1–30 min: 0% A, 100% B. The
flow rate was 0.5 mL·min−1. Ultra performance liquid chromatography-electrospray ionization-mass
spectrometry (UPLC-ESI-MS) was performed on a Waters Acquity UPLC System coupled to a Bruker
high capacity ion trap mass spectrometer (HCTM), using an Acquity UPLC ethylene bridge hybrid
(BEH) C18 1.7 µm (2.1 × 50 mm) column. UPLC solvents were formic acid (0.1% in millipore water)
(solvent A) and acetonitrile HPLC grade (solvent B). Applied UPLC gradient: 0–0.5 min: 95% A, 5% B;
0.51–4.0 min: linear gradient from 95% A (5% B) to 0% A (100% B); 4–5 min: 100% B. The flow rate was
0.6 mL/min. Detection was performed at 250 nm and 480 nm (diode-array detector). For preparative
HPLC, a Varian ProStar 320 system (Varian Inc, Palo Alto, USA) was used with a Dr. Maisch Reprosil
C18 100-7 (40 × 250 mm) column. The solvents (HPLC grade) were 0.1% trifluoroacetic acid (solvent
A) and acetonitrile (solvent B). Applied HPLC gradient: 0–2 min: 66% A (34% B); 2–45 min: linear
gradient from 66% A (34% B) to 0% A (100% B); 45–51 min: 100% B. The flow rate was 40 mL/min.
Detection was performed at 235 nm.
IR spectra were recorded on a Perkin-Elmer FT-IR Spectrum Two spectrometer (Perkin-Elmer Inc.,
Waltham, USA), using ATR technique and applied as neat samples.
Nitrogen sorption isotherms were collected at 77 K using a Quantachrome NOVA 3000
(Quantachrome Instruments, Boynton Beach, USA). Samples were vacuum-degassed at 80 ◦C for
3 h. The total specific surface area was calculated by the Brunauer-Emmett-Teller (BET) method [62].
Mesopore size distributions were evaluated by the nonlocal density functional theory (NLDFT)
method [63] developed for silica exhibiting cylindrical pore geometry (NOVAWin software, Version
11.0, Quantachrome Instruments, Boynton Beach, USA). The adsorption branch of the respective
isotherm was used for the calculations.
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The fluorescence and CLSM setup consisted of an Olympus BX60 microscope equipped with a
FluoView FV300 confocal unit and lasers operating at 488 and 543.5 nm.
UV–Vis spectra were measured on a Cary 50 UV–Vis spectrometer or a SPECORD® 250 PLUS
spectrometer (Analytik Jena, Jena, Germany) with solution samples in 1 cm quartz cells.; λmax
(ε) in nm; ε in M−1·cm−1. Fluorescence spectra were recorded with a LS 50 B Luminescence
spectrometer (Perkin-Elmer Inc., Waltham, USA); λem (λex) in nm. Lifetime and transient absorption
measurements were recorded on a LP920-K laser flash photolysis transient absorption spectrometer
using a flash-lamp-pumped, Q-switched Nd:YAG laser (355 nm) as the excitation source. Probing
of the sample was conducted by a Xe920 probe lamp (450 W) and an xP920 pulsing unit module.
Argon-purged solution samples in 1 cm quartz cells were used.
Microwave reactions were performed with a Biotage Initiator+ Robot Eight (Biotage, Uppsala,
Sweden) or Anton Paar Monowave 200 instrument (Anton Paar GmbH, Graz, Austria).
Automated C18 column flash chromatography was run on a Flash Master Solo with an Argonaut
UV–Vis detector from Omnilab and a Gilson FC 204 fraction collector. Separations were achieved
by using C18 silica gel from Supelco packed into an ISOLUTE reservoir (70 mL) from Biotage. Flash
column solvents were bidistilled water (solvent A) and MeOH (solvent B). Applied flash column
gradient: 0–10 min: 90% A, 10% B; 10–70 min: linear gradient from 90% A, 10% B to 0% A, 100%
B; 70–90 min: 0% A, 100% B. The flow rate was 2.0 mL·min−1. Detection was performed at 220 to
240 nm. ICP-MS measurements were performed on an Agilent QQQ 8800 Triple quad spectrometer
(Agilent Technologies, Santa Carla, USA), equipped with standard x-lens settings, nickel cones, and
a “micro-mist” quartz nebulizer. All solutions were prepared from 60% HNO3 (Merck 1.1518.500
ultrapure) and 18.2 MΩMillipore water (Merck KGaA, Darmstadt, Germany). Re (Merck 1.70344.0100
H2O) was measured against a series of dilutions of single element standards (0–250 ng/mL).
Crystallographic data were collected at 183(2) K on a Rigaku OD XtaLAB Synergy Dualflex
diffractometer (Rigaku Europe SE, Neu-Isenburg, Germany) equipped with a Pilatus 200 K detector and
a PhotonJet Cu Kα source (λ= 1.54184 Å) or Mo Kα source (λ= 0.71073 Å). Suitable crystals were covered
with oil (Infineum V8512, formerly known as Paratone N), placed on a nylon loop that was mounted
in CrystalCap Magnetic™ (Hampton Research), and immediately transferred to the diffractometer.
The program suite CrysAlisPro was used for data collection, multi-scan absorption correction, and
data reduction [64]. The structures were solved with direct methods using SHELXS-97 [65] and were
refined by full-matrix least squares methods on F2 with SHELXL-2014 [66]. The GUI ShelXle was
employed [67].
For NMR, ICP-MS, and (HR)-ESI-MS measurements of functionalized silica particles, a precise
amount of these particles (typically 5–10 mg) were decomposed at room temperature for 1–20 h in 1 M
NaOD in D2O (typically 0.7 mL) for NMR or 1M NaOH (typically 0.7 mL) for MS.
Detailed synthetic procedures for all reported reactions as well as control reactions are described
in the supplementary information.
3.1. Synthesis of 1d
The 2-quinolinecarboxaldehyde (825 mg, 5.25 mmol) was dissolved in 1,2-dichloroethane (28 mL)
and 4-aminobutyric acid (258 mg, 2.50 mmol) was added and stirred for 2 h at room temperature.
Sodium triacetoxyborohydride (1.219 g, 5.75 mmol) was added and the solution was stirred at r.t.
for 3 h. The 1,2-dichloroethane was evaporated in vacuo, the crude product was redissolved in
dichloromethane (25 mL), and washed with H2O (3 × 25 mL). The organic phase was dried in vacuo
and purified by flash chromatography over C-18 silica, resulting in 1d (277 mg, 0.719 mmol, 29%).
HR-MS (ESI): calcd. for [C24H23N3O2+H]+: 386.18630, found: 386.18664. 1H-NMR (400 MHz,
CDCl3) δ = 8.08–8.06 (m, 4H), 7.73 (d, J = 8.1 Hz, 2H), 7.68–7.61 (m, 4H), 7.48 (t, J = 7.5 Hz, 2H), 4.05 (s,
4H), 2.75 (t, J = 6.1 Hz, 2H), 2.37 (t, J = 6.6 Hz, 2H), 1.95–1.89 (m, 2H). 13C NMR (126 MHz, CDCl3)
δ = 177.13, 159.22, 147.41, 136.98, 129.78, 128.75, 127.67, 127.49, 126.53, 121.53, 60.84, 54.82, 34.20, 22.54.
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IR: 3061w, 2946w, 2814w, 1957w, 1701m, 1620w, 1598m, 1564w, 1504m, 1428m, 1308w, 1240m, 1112m,
907w, 826s, 732s.
3.2. Synthesis of 2
The 1d (28 mg, 0.07 mmol), 3-aminopropyltriethoxysilane (17.7 mg, 18.7 µL, 0.08 mmol) and
hexafluorophosphate benzotriazole tetramethyl uronium (82.6 mg, 0.22 mmol) were dissolved in dry
DMF (3 mL) and N,N-diisopropylethylamine (28 mg, 37.24 µL, 0.22 mmol) was added. The mixture
was stirred at r.t. for 2 h. The organic phase was washed with H2O (3 × 10 mL), filtered, and the DMF
was evaporated under reduced pressure to yield 2 (35 mg, 0.06 mmol, 85%).
HR-MS (ESI:) calcd. for [C33H45N4O4Si+H]+: 589.32119, found: 589.32046. 1H-NMR (400 MHz,
CDCl3) δ = 8.08 (d, J = 8.5 Hz, 2H), 8.04 (d, J = 8.4 Hz, 2H), 7.77 (d, J = 8.1 Hz, 2H), 7.68 (t, J = 7.6 Hz,
2H), 7.63 (d, J = 8.4 Hz, 2H), 7.50 (t, J = 7.5 Hz, 2H), 4.01 (s, 4H), 3.77 (q, J = 7.0 Hz, 6H), 3.10 (q, J = 6.6
Hz, 2H), 2.68 (t, J = 6.8 Hz, 2H), 2.17 (t, J = 7.4 Hz, 2H), 1.95–1.88 (m, 2H), 1.56–1.48 (m, 2H), 1.19 (t,
J = 7.0 Hz, 9H), 0.56–0.52 (m, 2H). 13C NMR (126 MHz, CDCl3) δ = 172.88, 160.55, 147.69, 136.40, 129.56,
129.12, 127.65, 127.45, 126.31, 121.41, 61.52, 58.56, 54.35, 41.97, 34.66, 23.81, 23.06, 18.42, 7.90.
3.3. Synthesis of 3
The 2-quinolinecarboxaldehyde (128 mg, 0.81 mmol) was dissolved in 1,2-dichloroethane (20 mL)
and 3-aminopropyltriethoxysilane (87 mg, 92 µL, 0.40 mmol) was added. The mixture was stirred at
25 ◦C for 2 h, sodium triacetoxyborohydride (252 mg, 1.18 mmol) was added, and the mixture was
stirred for 3.5 h at 25 ◦C. The 1,2-dichloroethane was evaporated in vacuo, EtOH (15 mL) was added,
and stirred for 10 min at 25 ◦C. The EtOH was evaporated in vacuo. The residue was washed with
toluene (20 mL) and the yellow solution was separated from the white precipitate by centrifugation.
The toluene was evaporated to yield crude 3. The product was purified by flash chromatography over
C-18 silica, leading to the isolation of 3 (99 mg, 0.197 mmol, 49%).
HR-MS (ESI:) calcd. for [C29H37N3O3Si+H]+: 504.26770, found: 504.26794. 1H-NMR (400 MHz,
CDCl3) δ = 8.11 (d, J = 8.5 Hz, 2H), 8.04 (d, J = 8.5 Hz, 2H), 7.78-7.74 (m, 4H), 7.67 (t, J = 7.6 Hz, 2H), 7.49
(t, J = 7.4 Hz, 2H), 4.02 (s, 4H), 3.72 (q, J = 7.0 Hz, 4H), 2.63 (t, J = 7.3 Hz, 2H), 1.72–1.64 (m, 2H), 1.14 (t,
J = 7.0 Hz, 9H), 0.58–0.54 (m, 2H). 13C-NMR (126 MHz, CDCl3) δ = 161.0, 147.7, 136.4, 129.5, 129.2,
127.6, 127.5, 126.2, 121.2, 61.7, 58.5, 58.0, 20.8, 18.4, 8.1. 29Si-NMR (99.36 MHz, CDCl3): δ = −45.01 ppm.
IR: 2975w, 2928w, 2881w, 1600m, 1506m, 1429w, 1390w, 1313w, 1164w, 1100s, 1074s, 950m, 831m, 767s.
3.4. General Procedure for the Synthesis of {Re(CO)3}+ Complexes
Between 0.15 and 0.01 mmol of the ligands (1a, 1b, 1e, and 3) were dissolved in 1 to 5 mL MeOH
([(3)Re(CO)3]+ = EtOH) and equimolar amounts of (NEt4)2[ReBr3(CO)3] were added. A microwave
vial containing the reaction solution was purged with N2 for 5 min. The mixture was heated to 85 ◦C
(110 ◦C for [(1e)Re(CO)3]+ and [(3)Re(CO)3]+) for 45 min in a microwave reactor. H2O was added to
the vial and the formed precipitate was removed by filtration or centrifugation. From the clear solution,
the product was precipitated by the addition of NH4PF6 as the corresponding PF6 salt and collected by
filtration or centrifugation. The [(3)Re(CO)3](PF6) was directly precipitated from the aqueous solution
by the addition of NH4PF6. The products were washed with several mL of H2O and dried under
high vacuum.
3.4.1. Analytical Data for [(1a)Re(CO)3](PF6)
HR-MS (ESI:) calcd. for [C26H21N3O3Re]+: 610.11349, found: 610.11355. 1H-NMR (500 MHz,
CDCl3) δ = 8.48 (d, J = 8.8 Hz, 2H), 8.36 (d, J = 8.4 Hz, 2H), 7.90 (d, J = 8.0 Hz, 2H), 7.84 (t, J = 7.5 Hz,
2H), 7.66 (m, 4H), 6.31 (m, 1H), 5.77 (d, J = 16.8 Hz, 1H), 5.69 (d, J = 10.2 Hz, 1H), 5.08 (m, 4H), 4.32 (d,
J = 7.1 Hz, 2H). 13C-NMR (125 MHz, CDCl3) δ = 195.62, 194.14, 164.48, 147.11, 141.89, 133.24, 129.82,
129.59, 128.58, 128.54, 128.43, 127.34, 120.17, 70.42, 68.85. IR: 2026s (CO), 1903s (CO), 1712w, 1604w,
1516w, 1432w, 1369w, 1291w, 1217w, 1149w, 1124w, 948w, 835s 747w.
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Crystals suitable for X-ray diffraction analysis were obtained by vapor diffusion of cyclohexane
into a THF solution of [(1a)Re(CO)3](PF6).
3.4.2. Analytical Data for [(1b)Re(CO)3](PF6)
HR-MS (ESI:) calcd. for [C29H27N3O5Re]+: 684.15027, found: 684.14980. 1H-NMR (400 MHz,
CDCl3) δ = 8.49 (d, J = 8.7 Hz, 2H), 8.34 (d, J = 8.4 Hz, 2H), 7.91 (dd, J = 3.1 Hz, 2H), 7.85–7.81 (m, 2H),
7.66 (t, J = 7.2 Hz, 2H), 7.60 (d, J = 8.4 Hz, 2H), 5.25–5.13 (m, 4H), 4.48 (s, 2H), 1.45 (s, 9H). 13C-NMR
(125 MHz, CDCl3) δ = 195.54, 193.76, 166.65, 164.76, 147.02, 141.62, 133.15, 129.81, 128.59, 128.52, 128.30,
119.74, 84.83, 70.40, 66.83, 28.09. IR: 2159w, 2027s (CO), 1910s (CO), 1735w, 1519w, 1370w, 1243w, 1160m,
1034w, 844s, 780w.
Crystals suitable for X-ray diffraction analysis were obtained by vapor diffusion of cyclohexane
into a THF solution of [(1b)Re(CO)3](PF6).
3.4.3. Analytical Data for [(1e)Re(CO)3](PF6)
HR-MS (ESI:) calcd. for [C26H22N3O4Re]+: 628.12406, found: 628.12394. 1H-NMR (400 MHz,
CDCl3) δ = 8.47 (d, J = 3.1 Hz, 2H), 8.35 (d, J = 8.3 Hz, 2H), 7.89 (d, J = 3.2 Hz, 2H), 7.85–7.81 (m,
2H), 7.68–7.63 (m, 4H), 5.16–5.04 (m, 4H), 3.99–3.95 (m, 2H), 3.84 (t, J = 5.6 Hz, 2H), 2.30–2.23 (m, 2H).
13C-NMR (126 MHz, CDCl3) δ = 195.72, 194.15, 164.64, 147.10, 141.87, 133.21, 129.78, 128.59, 128.55,
128.43, 120.21, 68.70, 65.93, 59.80, 29.23. IR: 3617w, 2919w, 2025s (CO), 1932m (CO), 1897s (CO) 1597w,
1519w, 1435w, 1371w, 1306w, 1214w, 1126w, 1047w, 831s, 742m, 659m.
Crystals suitable for X-ray diffraction analysis were obtained by vapor diffusion of cyclohexane
into a THF solution of [(1e)Re(CO)3](PF6).
3.4.4. Analytical Data for [3-Re](PF6)
HR-MS (ESI:) calcd. for [C32H37N3O6ReSi]+: 774.20036, found: 774.20035. 1H-NMR (500 MHz,
CDCl3) δ = 8.46 (d, J = 8.8 Hz, 2H), 8.33 (d, J = 8.5 Hz, 2H), 7.88 (d, J = 8.0 Hz, 2H), 7.83–7.80 (m, 2H),
7.66–7.63 (m, 4H), 5.19–4.96 (m, 4H), 3.84 (q, J = 7.0 Hz, 6H), 2.16–2.10 (m, 2H), 1.58 (s, 2H), 1.20 (t,
J = 7.0 Hz, 9H), 0.75 (t, J = 7.7 Hz, 2H). 13C-NMR (126 MHz, CDCl3) δ = 195.8, 194.2, 164.7, 147.1, 141.8,
133.1, 129.8, 128.6, 128.5, 128.4, 120.3, 70.7, 68.7, 58.8, 20.4, 18.4, 7.7. 29Si-NMR (99.38 MHz, CDCl3):
δ = −47.44 ppm. IR: 2976w, 2891w, 2025s (CO), 1901s (CO), 1602w, 1517w, 1470w, 1436w, 1394w,
1300w, 1205w, 1163w, 1074m, 958w, 873w, 835s, 779m, 749m, 647w. UV–Vis (CHCl3, 10−5 M): 323 nm
(13696 M−1·cm−1). Fluorescence (CHCl3, 10−5 M): λex (326), λem air (426, 546), λem N2 (383, 566).
3.5. Synthesis of 3@SBA-15
SBA-15 particles (213 mg) were dried by heating (140 ◦C) under high vacuum for 4 h. Then,
3 (10 mg, 0.02 mmol) was dissolved in dry toluene (5 mL) and added to the SBA-15 particles. The
suspension was sonicated at 60 ◦C for 2 h. Filtration, washing with toluene (5 mL) and Et2O (5 mL),
and drying under high vacuum led to the isolation of 3@SBA-15 (176 mg).
EA: C 2.46, H 0.49, N 0.32. HR-ESI of dissolved particles (1M NaOD in D2O): calc. for
[C23H25O3N3Si+H]+: 420.17379, found: 420.17345. 1H-NMR (1M NaOD in D2O 500 MHz): δ = 7.76 (d,
J = 8.5 Hz, 2H), 7.56 (d, J = 8.3 Hz, 2H), 7.52–7.49 (m, 4H), 7.34 (t, J = 7.0 Hz, 2H), 7.24 (d, J = 8.5 Hz,
2H), 3.88 (s, 4H), 2.70 (t, J = 7.8 Hz, 2H), 1.72–1.69 (m, 2H), 0.38 (t, J = 8.4 Hz, 2H).
3.6. Synthesis of 3-Re@SBA-15
3.6.1. Method A: Grafting of 3-Re onto SBA15
SBA-15 particles were dried by heating (140 ◦C) under high vacuum for 4 h. The dry SBA-15
particles (200 mg) were dispersed in dry DCM (5 mL). The suspension was transferred into a microwave
vial and [3-Re](PF6) (9.2 mg, 0.01 mmol) was added. The suspension was sonicated for 2 h at 60 ◦C.
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After filtration, washing with DCM (3 mL), and drying under high vacuum, 3-Re@SBA-15 (202 mg)
was isolated.
EA: Found: C 2.70, H 0.57, N 0.21. IR: 2026w (CO), 1901w (CO), 1891w (CO), 1631w, 1053s (Si–O),
964m, 818w, 649w.
3.6.2. Method B: Reaction of (NEt4)2[Re(H2O)3(CO)3] with 3@SBA-15
(NEt4)2[Re(CO)3Br3] (38.4 mg, 0.050 mmol) was dissolved in H2O (6 mL) and AgNO3 (25.2 mg,
0.148 mmol) was added. The solution turned milky and a precipitate was formed immediately. After
stirring for 60 min at r.t. the precipitate was filtered. A clear solution [Re(H2O)3(CO)3]NO3 was
obtained (pH 6–7). This solution was added to 3@SBA-15 (80 mg) particles and the suspension was
heated at 100 ◦C for 45 min in a microwave reactor. Finally, 3-Re@SBA-15 (71 mg) was isolated by
filtration, washed with H2O (2 mL) and toluene (4 mL), and dried under vacuum.
EA: C: 2.28 H: 0.80 N: 0.30. Nitrogen sorption: BET: 217 m2/g; average pore size: 7.0 nm; total
pore volume: 0.43 cm3/g. IR: 2026w (CO), 1901w (CO), 1891w (CO), 1631w, 1053s (Si–O), 964 m, 818w,
649w. ICP-MS: 1.4% w; 0.077 mmol/g particles; 0.07 Re atoms/nm2.
3.7. Synthesis of Bifunctionalized Mesoporous Silica Particles (EOITC/3@SiP)
Silica particles (SiP = SBA-15, spherical sSBA-15) were dried by heating (140 ◦C) under high vacuum
for 4 h, then dispersed in hexane, and 3-aminopropyltris(methoxyethoxyethoxy)silane (APTMEES) was
added. The suspension was sonicated for 10 min at room temperature. The particles were recovered
by filtration, washed with hexane (3 × 3 mL), and dried under high vacuum, yielding APTMEES@SiP.
Eosin isothiocyanate (EOITC) was dissolved in EtOH (10 mL). APTMEES@SiP particles were added
and the suspension was stirred at r.t. for 16 h. The particles were collected by filtration, washed with
EtOH (50 mL) and H2O (50 mL), yielding EOITC/@SiP. Then, 3 was dissolved in dry toluene and added
to dry EOITC/@SiP particles. The suspension was sonicated at 40 ◦C for 2 h. Finally, EOITC/3@SiP
was filtered off, washed with toluene (5 mL) and Et2O (5 mL), and dried under high vacuum.
3.8. Reaction of Bifunctionalized Mesoporous Silica Particles (SiP) with [Re(H2O)3(CO)3]+
The (NEt4)2[Re(CO)3Br3] was dissolved in H2O and 3 equiv AgNO3 were added. A colorless
precipitate was formed immediately. After stirring for 60 min at r.t. the precipitate was filtered off.
A clear solution of [Re(H2O)3(CO)3]NO3 was obtained (pH 6–7). This solution was added to the
EOITC/3@SiP (SiP = SBA-15, spherical sSBA-15) and the suspension was heated at 100 ◦C for 45 min
by means of a microwave reactor. The formed EOITC/3-Re@SiP particles were collected by filtration,
washed with H2O (2 mL) and toluene (4 mL), and dried under vacuum.
3.9. Labeling of Bifunctionalized Mesoporous Silica Particles (SiP) with [99mTc(H2O)3(CO)3]+
A microwave vial was charged with EOITC/3@SiP (SiP = SBA-15, sSBA-15) (10 mg) and saline
(2 mL). The vial was flushed with N2 (5 min). The [99mTc(H2O)3(CO)3]+ (5–15 MBq) in saline (2 mL,
pH 7) was added and the suspension was heated at 100 ◦C for 15 min in the microwave reactor. For
reaction control, an aliquot (0.5 mL) was filtered and centrifuged, and the clear solution was used for
radio-HPLC measurements. As an additional control, 10 µL of each centrifuged sample was collected
and the remaining activity in solution was determined by means of a γ-counter.
4. Conclusions
We combined the multimodal properties of the bisquinoline/{M(CO)3}+ system (M = 99mTc, Re)
with the theranostic properties of the 99mTc/186/188Re pair at a mesoporous silica support. The presented
synthetic procedures are based on fundamental studies, which disclosed the most suitable mesoporous
silica construct (SBA-15) for this development. Furthermore, a variety of different pathways was
developed to synthesize bisquinoline-containing silanes, suitable for grafting reactions with silica
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particles. The hydrolysis of the trialkoxysilane moiety and subsequent cross-linking of the products
had to be addressed. The successful functionalization of the external and the pore surface of the
mesoporous silica particles was visualized by confocal laser scanning microscopy. The synthesized
model system mimics a SBA-15-based target-specific theranostic nanoplatform, which enables the
combination of fluorescence and radio imaging with the possibility of radio- and chemotherapy.
Currently, we are using the reported procedures to synthesize target-specific nanoparticles for the first
in vitro and in vivo studies.
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